Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide for primary liver cancer with lung metastases
ChiCTR-ONRC-12003187Phase 4Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of arsenic trioxide in hepatocellular carcinoma (HCC) and lung metastases (LM) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Objective response rate of lung metastases and Safety. Started May 2012; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
hepatocellular carcinoma (HCC)lung metastases (LM)
Beyond the preview
Go deeper on ChiCTR-ONRC-12003187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-12003187.